Last reviewed · How we verify
Bevacizumab + Pemetrexed + Carboplatin
This combination uses a monoclonal antibody to block tumor blood vessel formation while two chemotherapy agents work synergistically to kill cancer cells.
This combination uses a monoclonal antibody to block tumor blood vessel formation while two chemotherapy agents work synergistically to kill cancer cells. Used for Non-squamous non-small cell lung cancer (NSCLC), first-line metastatic disease.
At a glance
| Generic name | Bevacizumab + Pemetrexed + Carboplatin |
|---|---|
| Also known as | Avastin®, ALIMTA®, Carboplatin |
| Sponsor | PD Dr. med. Wolfgang Schuette |
| Drug class | Combination therapy: monoclonal antibody (anti-VEGF) + antifolate chemotherapy + platinum chemotherapy |
| Target | VEGF (bevacizumab); thymidylate synthase and other folate-dependent enzymes (pemetrexed); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a VEGF inhibitor that starves tumors of blood supply by blocking angiogenesis. Pemetrexed and carboplatin are platinum-based chemotherapy agents that work through different mechanisms—pemetrexed inhibits folate-dependent enzymes while carboplatin causes DNA cross-linking—providing complementary cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Non-squamous non-small cell lung cancer (NSCLC), first-line metastatic disease
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea/vomiting
- Peripheral neuropathy
- Bleeding events
- Hypertension
Key clinical trials
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease (PHASE2)
- Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: